HOME > BUSINESS
BUSINESS
- Astellas President Hatanaka Says Company Can Continue on Growth Path Through 2014
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
- Asahi Kasei Pharma’s Apr-Sep Sales Up 6% Due to Doubled Recomodulin Sales
November 4, 2011
- Once-Yearly Dosing Osteoporosis Agent Starts PIII Study: Asahi Kasei Pharma
November 4, 2011
- FDA Assigns Action Date of Jan 25, 2012 for Takeda’s Alogliptin
November 4, 2011
- Sales of Medical & Pharmaceutical Business Increased 2.4% Driven by New Drugs: Teijin
November 4, 2011
- Astellas: Sales, Profits Up in First Half Driven by Vesicare
November 4, 2011
- Eisai Announces Double-digit Declines in 1st-Half Sales, Profits
November 4, 2011
- Kaken: Mainstay Products, Generics Pull Business
November 4, 2011
- Santen Sends Expert Researchers to US, Europe to Assess Candidate Compounds for In-licensing
November 4, 2011
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…